Neovascular age-related macular degeneration (nAMD) remains the leading cause of blindness for individuals above the age of 65 in the United States and in many similarly developed countries despite the availability of highly effective therapies targeting vascular endothelial growth factor (VEGF) [1,2]. This evidence concerns the gene VEGFA and blindness (disorder).